Want to stay at the cutting edge of scientific research and drug development? Our CEO, Dr Chris Burns FAHMS, is sharing fascinating insights over on BlueSky about the latest developments in targeted therapies, with a particular focus on the potential of FAK inhibitors in treating various diseases. Join the conversation and follow Dr Burns to dive deeper into the science and engage with thought-provoking discussions on the future of therapeutic development.
Ann: Completion of Recruitment of ACCENT Trial, page-33
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.005(2.78%) |
Mkt cap ! $67.89M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 21.0¢ | 17.0¢ | $2.549M | 13.34M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 73164 | 4 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| ATX (ASX) Chart |